Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Paige Partridge

Obstetrics & Gynecology Johnson, AR Medical Doctor

NPI 1568437101 CMS profile 343729

4301 Greathouse Springs Rd, Suite 100, Johnson, AR 72741

Open in the dashboard

General payments

$49,918

192 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Paige Partridge of Johnson, AR is reported in the CMS Open Payments database as having received $49,918 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $4,111 5
2022 General $44,323 103
2021 General $1,041 58
2020 General $237 12
2019 General $205 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paige Partridge
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Paige Partridge were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Paige Partridge Obstetrics & Gynecology median Middle half National median
2019 $205 $172 $62–$391 $163
2020 $237 $94 $36–$222 $114
2021 $1,041 $136 $42–$369 $132
2022 $44,323 $160 $50–$433 $149
2023 $4,111 $169 $56–$423 $160
2024 $0 $152 $50–$371 $164
2025 $0 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Applied Medical Resources Corporation $45,473 50 payments
  2. Memic Innovative Surgery Inc. $1,876 3 payments
  3. AbbVie, Inc. $1,029 68 payments
  4. Caldera Medical, Inc $260 3 payments
  5. Gynesonics, Inc. $157 1 payment
  6. Exeltis, USA Inc. $149 10 payments
  7. Pfizer Inc. $144 11 payments
  8. Mayne Pharma Inc. $134 9 payments
  9. Hologic, LLC $112 7 payments
  10. Baxter Healthcare $109 2 payments
  11. Other $475 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,000 16 payments
  2. Travel and Lodging $10,427 19 payments
  3. Food and Beverage $3,477 155 payments
  4. Education $14 2 payments
Products named General payments · program years 2019–2023
  1. GELPOINT V-PATH Specialty Access $25,124 21 payments
  2. GelPOINT V-Path Specialty Access $16,485 24 payments
  3. GelPOINT V-Path Specialty Access $3,873 5 payments
  4. Anovo Surgical System $1,876 3 payments
  5. ORIAHNN $386 20 payments
  6. ORILISSA $283 16 payments
  7. Desara $260 3 payments
  8. LO LOESTRIN FE $228 16 payments
  9. SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM $157 1 payment
  10. PREMARIN $156 12 payments
  11. Other $1,403 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

34

Median for Obstetrics & Gynecology: 65

Drug cost

$829

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

47.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 18 $514
Progesterone Progesterone, Micronized Brand 16 $315

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record